product stronger market onward
total revenu y/i fx well ahead
street estim organ growth impress vs
estimate beat broad-bas end-market geographi product categori gross
opmargin declin yoy bit expect due
pthn deal fx mix adj ep still street
includ increment invest non-op item beat larg
expect given market trend better even bullish expect
underscor tmo strong fundament first look detail
growth keep acceler outlook posit
end-market continu grow unison seem take meaning share
notabl pharma grew high-teen quarter china
anoth sale growth quarter despit tough comp given certain
competitor result benefit improv academ government spend
us look early-stag upcycl given improv nih
fund china biomed invest grow market
environ strength tmo portfolio global busi amplifi
everi data-point indic setup key focu investor still
favor improv organ growth profil margin runway capit
deploy option lever end see share well-posit
reiter buy rate see tmo divers underappreci strength
rais estim see organ out-year
rais organ sale guid anoth adj ep
mdpt vs prior larg captur beat also increas
outlook modestli estimate sale y/i organ
fx adj ep y/i sale
organ adj ep yoy po dcf base w/ wacc
termin growth rate unchang
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
thermo fisher scientif largest
consist analyt instrument lab
equip consum softwar servic
use throughout research drug manufactur
diagnost food consum product safeti
environment test
thermo fisher scientif largest life scienc
tool compani think recent acquisit
complementari technolog higher growth
on-going process improv initi
expand footprint emerg appli
market help grow revenu steadili
line even modestli better
overal tool market deliv low teen ep
compound-annual-growth-rate next sever year
po base dcf model assum wacc termin
growth rate impli multipl approxim ep estim in-lin
compani peer group averag given size market leadership matur
stabil compani consum focus busi believ dcf
appropri way valu compani risk price object deal
integr risk lower-than-expect deal synergi slower growth emerg
market price eros lower healthcar util trend soft uptak new
product competit weak fund
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
